What happened
The U.S. Food and Drug Administration has cleared Medtronic's Hugo robotic-assisted surgery system for general surgery, allowing the modular, cart-based robot to operate across the abdomen, The Robot Report reported. The clearance covers every upper abdominal general surgical procedure, among them cholecystectomy, Roux-en-Y gastric bypass, ventral hernia repair and small bowel resection, along with inguinal hernia repair and appendectomy in the lower abdomen.
According to Medtronic, these procedures together amount to roughly 3.5 million operations a year in the U.S. Rajit Kamal, general manager of robotic surgical technologies at Medtronic, said the company took two routes to the clearance: a U.S. clinical trial conducted under an investigational device exemption, and data gathered from Hugo's use outside the U.S. He said this combination yielded a wider set of general surgery indications.
Kamal said Medtronic plans to bring AI features onto Hugo. He described a role for AI before surgery in planning procedures, during surgery in identifying critical anatomy and guiding surgeons, and afterward in optimizing recovery. He added that wider access to robotic surgery depends on cost, training and support, and that Medtronic is willing to work with hospitals on the financial case for adopting the system.
Context
Hugo received FDA approval for urology in December 2025, and in September 2025 Medtronic said a U.S. hernia repair study had hit its safety and effectiveness goals. Hugo has carried CE marking for general surgery in Europe since 2022, and general surgery is its fastest-growing procedure category outside the U.S. Medtronic also holds FDA approval for Touch Surgery Aide, an AI platform that analyzes surgical video in real time.
Das Briefing
Die Tech-Woche in einer E-Mail.
Die lesenswerten Beiträge der Woche. Jederzeit abbestellbar.
